Aim: Nonstent drug delivery platforms have recently emerged as an alternative treatment of peripheral arterial disease. Perfusion catheters have the potential to directly deliver antiproliferative agents to the medial arterial layer to prevent restenosis. The purpose of this study was to therefore determine the effectiveness of a perfusion catheter to deliver paclitaxel, a proven antiproliferative agent, to combat restenosis.
| INTRODUCTION
The treatment of peripheral arterial disease (PAD) costs the US roughly $21 billion annually and affects more than five million people. Despite this sizeable economic investment, treatment outcomes remain poor.
Percutaneous intervention, balloon angioplasty and stenting, is the preferred choice to treat PAD due to reduced morbidity, mortality, and in-hospital stay as compared to bypass surgery. 1, 2 However, results are suboptimal with high rates of restenosis, 3 re-occlusion of the treated artery. Historically, stent fractures, either drug coated or bare, are a big contributor to this poor performance with reported restenosis rates up to 76% in fractured stents. 4, 5 More recent data demonstrate superficial femoral stent fracture rates of 12.5%-30%, with associated restenosis rates of 10%-56.6%. 6, 7 The use of stents for below-the-knee (BTK) applications is also limited due to long lesion length (130-170 mm)
of BTK lesions, requiring multiple stents. BTK stent implantations are thus primarily used as bailout strategy in case of flow limiting dissection or recoil. 8 Treatment of BTK vessels is essential for limb salvage in diabetic patients with PAD. 9, 10 In these instances, balloon angioplasty is the only option; however, restenosis rates of balloon angioplasty are inferior to stents. [11] [12] [13] [14] [15] [16] [17] [18] [19] The recently approved drug-coated balloon (DCB) has emerged as an alternative strategy to treat femoropopliteal segments. 20 DCB delivers antiproliferative agents, such as paclitaxel, in combination with excipients (drug carriers) to the arterial wall. 21, 22 Excipients thus play an essential role in the delivery and retention of paclitaxel in nonstent drug delivery platforms. The fundamental approach of DCB, however, is similar to drug eluting stents (DES) in that the antiproliferative drugs are stored on the intima, leading to potential problems in delayed healing, poor endothelialization, and the potential for thrombosis. 23 Furthermore, coating design and choice of excipient of DES in addition to the wide range of biomechanical movement in peripheral arteries 24 have the potential to dislodge the drug/excipient at the luminal surface (emboli) and occlude smaller arteries downstream. This may be particularly detrimental for a diabetic patient with very poor foot circulation. [25] [26] [27] Both DES and DCB are also limited as they are designed as a single-use device, delivering antiproliferative drugs only to one location.
The Occlusion Perfusion Catheter™ (OPC™, Advanced Catheter
Therapies, Chattanooga, TN, USA) is a novel multilumen catheter designed to occlude the target lesion from blood flow, flush the blood from the treatment chamber, and then locally deliver the therapeutic agents into the vessel. The delivery of therapeutic agent is then accomplished by pressure differences created by an increase in luminal pressure by the perfusion catheter thereby driving the drug molecules across tissue layers into the medial wall. The potential benefit of this approach is that it avoids the accumulation of antiproliferative drugs on the luminal surface, as the drug is delivered into the medial wall.
The design of the perfusion catheter also permits treatment of multiple sites with a single device in the same patient.
The purpose of this study was to therefore determine the effectiveness of the OPC™ perfusion catheter to deliver paclitaxel, a proven clinical antirestenotic agent. 28 Specifically, parameters impacting the delivery and retention of paclitaxel were investigated using benchtop and a clinically relevant preclinical model.
| METHODS

| Benchtop bioreactor system
Twenty-eight porcine carotid arteries were harvested from large pigs (110-160 kg) from a local abattoir (Semmes, AL, USA) and transferred in sterile PBS with 1% antibiotics-antimitotics (Gibco, Grand Island, NY, USA). Vessels were then rinsed in sterile PBS in a culture hood.
The excess fat, connective tissue, and fascia were removed from each vessel. Vessels were cut into approximately 8 cm segments and stored in 15-mL centrifuge tubes at −20°C until needed. Frozen vessels were thawed in a 37°C water bath and placed into the bioreactor system to be studied.
The bioreactor system used in this study consisted of a flow reservoir, pump, vessel housing compartment, and a distal flow constrictor 
| Drug delivery via perfusion catheter
To deliver paclitaxel locally to selected regions, a multilumen balloon perfusion catheter (Advanced Catheter Therapies) was utilized.
Prior to paclitaxel delivery, ex vivo arteries underwent endothelial denudation using an angioplasty balloon catheter (5.0 mm×15 mm).
The perfusion catheter can temporarily occlude the target area from blood flow by deploying occlusion balloons ( Figure 2 ). The treatment chamber can then be flushed to remove trapped blood. Following flushing of the treatment chamber, therapeutic agents/drugs can then be delivered to the treatment chamber. The delivery of therapeutic agent is accomplished by pressure differences created by an increase in luminal pressure by the perfusion catheter thereby driving the drug molecules across tissue layers into the medial wall.
Paclitaxel (6.0 mg/mL, Sagent Pharmaceuticals, Schaumburg, IL, USA) was delivered to each harvested artery at varying concentrations ranging from 1.2 to 6.0 mg/mL. The 6.0 mg/mL paclitaxel concentration was the maximum (stock) solution of the liquid paclitaxel, and the 1.2 mg/mL was the manufacturer recommended dilution of paclitaxel, and 3.6 mg/mL was the median value. Lower concentrations (<6.0 mg/mL) were achieved by diluting paclitaxel with saline and iohexol (Ominipaque™, GE Healthcare, Wauwatosa, WI, USA), which served as an excipient. Specifically, to dilute the solution to lower concentrations, the 6 mg/mL was diluted in saline at a ratio of 1:4 (1-part paclitaxel, four-part saline) to achieve a 1.2 mg/mL and 3:2 (three-part paclitaxel, two-part saline) to achieve a 3.6 mg/ mL paclitaxel concentration. For the excipient portion, the solution was diluted at a ratio of 3:1:1 (three-part paclitaxel, one-part saline, one-part iohexol). 
| Rabbit injury model
| Arterial sections
To demonstrate drug penetration by the perfusion device, ex vivo arterial segments were cut from the arterial test section and F I G U R E 2 Schematic illustration of the perfusion catheter. Two occluding balloons are deployed to momentarily stop circulating flow to a portion of a vessel. Trapped blood within the perfusion chamber is then flushed with saline. Drug can be delivered through the inflow port. The outflow port can be closed and drug delivered to the lesion with external pressure. The delivery pressure is measured by a fiber-optic pressure sensor located at the inlet port. Following the delivery of the drug, the remaining drug in the chamber is cleared through the outflow port to ensure no additional drug is introduced into the circulatory system frozen fresh in optical cutting temperature (O.C.T.) compound (Sakura Finetek USA, Inc., Torrance, CA, USA 
| Quantification of paclitaxel tissue concentrations
For quantification of paclitaxel, a previously described, validated high-performance liquid chromatography (HPLC)-electrospray ionization-tandem mass spectrometry system (LC-MS/MS) was used. 30 The tissue concentrations were calculated based on the peak area ratios of paclitaxel and its internal standard. A quadratic regression equation with 1/x weighting was used. The range of reliable response was 0.5-100 ng/mL tissue homogenate. Interday imprecision was less than 15%, and accuracy was within 85%-115% of the nominal concentrations. There were no significant matrix interferences, carryover, or matrix effects.
| Statistical analysis
All values were expressed as mean±standard deviation (SD).
Quantitative data were compared with analysis of variance (ANOVA)
using GrapPad Prism 7 (GraphPad Software, La Jolla, CA, USA).
Comparison of multiple groups was performed by Tukey's multiple comparisons post hoc test. A value of P<.05 was considered statistically significant. To visualize drug penetration, fluorescent paclitaxel (Flutax-1, 0.1 mg/mL) was delivered with and without excipient. Representative images using confocal microscopy demonstrated uniform circumferential delivery of the Flutax-1 using the OPC perfusion catheter, although less penetration into the medial layer was observed with the excipient group (Figure 3 ).
| RESULTS
| Benchtop modeling
| Preclinical animal modeling
Following ex vivo studies, parallel in vivo studies were performed using the rabbit ilio-femoral injury model to determine the impact of excipient on arterial paclitaxel retention. Arteries were treated with either paclitaxel alone (Group I) or paclitaxel with an excipient (Group IV) using the OPC perfusion catheter. An angiogram of the perfusion catheter within the ilio-femoral artery is shown in Figure 4 . Table 2 summarizes the arterial concentration (ng/mg) results of the rabbit 
| DISCUSSION
This study was designed to evaluate, for the first time, the drug delivery of a novel occlusion perfusion catheter and the impact of varying parameters (delivery pressure, drug concentration, duration time) and excipients on the uptake of paclitaxel using an ex vivo and in vivo rabbit ilio-femoral injury model. Both models utilized healthy vessels 27 Additionally, drug-coated balloons have had suboptimal outcomes in BTK studies. 34 In these scenarios, developing alternative strategies to treat patients with PAD is of significant value.
One of the main commonality of the varying strategies to treat PAD is the use of paclitaxel, a highly potent antiproliferative that has
shown to be effective in the short, single-dose approach. 35 The perfusion catheter shares similar traits with the drug coated balloon as it delivers paclitaxel in a short and single-dose manner using established clinical catheter techniques; however, the paclitaxel agent is in liquid form as compared to dry or powdered paclitaxel form. The benefit of such a liquid solution is the ability to deliver antiproliferative drugs directly into the medial layer, as observed in Figure 3 .
Additionally, this approach eliminates any potential loss of drug in transit/tracking, allows multiple treatments per patient, and reduces the risk of embolization as observed in drug coated balloon coating/ excipient.
In this study, the well-established swine and rabbit arteries were utilized to test the pharmacokinetic profiles of the perfusion catheter. 36, 37 In the ex vivo portion of the study, we varied the loading parameters of the perfusion catheter to determine parameters to maximize paclitaxel retention acutely (1 hour). The paclitaxel concentration selected were 6.0 mg/mL, the maximum (stock) solution of the liquid paclitaxel, and 1.2 mg/mL, the manufacturer recommended dilution of paclitaxel. The 3.6 mg/mL was the median value. We additionally tested the impact of increasing duration of delivery from 2 to Following the ex vivo studies, a clinically relevant preclinical model was used to further demonstrate the capabilities of the perfusion catheter. 37, 38 The in vivo comparator groups were Group I and Group IV, which represented a drug mixture with and without an excipient with similar ex vivo 1-hour paclitaxel loading conditions. The excipient, the contrast media iohexol, was intended to increase residency of paclitaxel as previous nonstent platform studies had indicated paclitaxel alone is not sufficient for long-term residency. 8.9±6.9 ng/mg, P=.99) groups were similar.
As mentioned previously, the contrast media iohexol was utilized to enhance paclitaxel delivery. Although other studies have demonstrated similar favorable paclitaxel uptake and retention in the use of contrast media, 39,40 the potential mechanism has not been described.
Iohexol, a nonionic contrast agent, possesses lipophilic zones, in Pressure is the main driving force that delivers the liquid paclitaxel mixture to the medial layer of the target lesion. For this study, pressure was generated by the delivery of the liquid paclitaxel into the treatment chamber through the inflow port ( Figure 2 ). Pressure generated in the treatment chamber is dependent on the treatment chamber size, arterial compliance, lesion complexity, presence of side branches within the treatment chamber, and viscosity of the drug mixture. For the in vivo studies, the measured treatment pressure chamber ranged from was 0.47 to 2.0 atm. This pressure was measured using a built-in fiber optic pressure within the treatment chamber. In clinical settings however, the presence of bifurcations and branches may reduce the treatment chamber pressure during delivery of the drug. To determine whether varying treatment pressure chamber impact drug penetration, additional ex vivo studies were performed that delivered the fluorescent paclitaxel at treatment chamber pressures ranging from 0.2 to 1.0 atm. In all cases, drug was able to penetrate into the medial layer, although the depth of penetration was dependent on the treatment chamber pressure ( Figure 5 ). Further studies on the relationship between treatment chamber pressure, drug viscosity, and lesion characteristics are warranted to better understand and optimize local drug delivery using perfusion catheters.
The use of liquid paclitaxel to treat PAD has been utilized in prior studies. Of importance was the THUNDER (local taxane with short exposure for reduction of restenosis in distal arteries) trial, which demonstrated a reduction in 6-month late lumen loss of paclitaxelcoated drug-coated balloon as compared to balloon angioplasty. 42 In the same trial, however, paclitaxel-contrast liquid solution (approximately 100 mL of contrast/paclitaxel medium added to circulation via a catheter injection) had similar results to balloon angioplasty.
On the contrary, a more recent study has demonstrated effectiveness of liquid paclitaxel to treat patients with critical limb ischemia.
43
In this single-center, single-blind, randomized trial, patients treated with local liquid paclitaxel (mixed with contrast agent) had less restenosis and amputation as patients treated with drug-coated balloon.
The liquid paclitaxel, delivered following ultrasound treatment, was delivered stagnantly (using balloon to close of distal outlets) for 60 seconds at the lesion site. These studies highlight differences in delivery mechanism of liquid paclitaxel and its relationship to clinical outcomes.
This study was limited to a healthy animal model and thus did not take into consideration diseased arteries as observed in patients with PAD. The perfusion catheter-treated arteries lack major side branches and bifurcations, which may not represent all clinical settings. Human lesions are more complex and often include fibrosis, calcification, hemorrhage, and in most cases require de-bulking using balloons and atherectomy devices. The impact of intact endothelium (noninjured) on paclitaxel-excipient penetration was not determined. Nevertheless, preclinical studies involving healthy arteries are the standard model to determine pharmacokinetic of cardiac and stent-based intervention devices.
| CONCLUSIONS
This study provides first evidence of the use of an occlusion perfusion catheter to deliver liquid paclitaxel uniformly into the medial wall of an artery using both ex vivo and in vivo models. The results showed that the addition of an excipient increases arterial paclitaxel residency.
Further studies are warranted to demonstrate the safety and efficacy profile of the perfusion catheter up to 28 days. Overall, this approach has the potential to improve interventional outcomes and quality of life of millions of patients suffering with PAD.
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